4,901 trials
Locally Advanced Lung Non-Small Cell Carcinoma · Locally Recurrent Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8
Primary: Number of Participants Experiencing a Safety Event — 0; 1 Participants
Prevention or Reduction of HIV Risk Behavior · Prevention or Reduction of Intimate Partner Violence
Primary: Number of Participants Who Expressed Satisfaction With the Intervention — 113 Participants
Chronic Post-stroke Headache
Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896
Ophthalmological Agent Toxicity · Bacterial Conjunctivitis
Primary: Incidence of Unexpected Adverse Events Related to the Interventions — 1; 4 number of related adverse events
Hepatic Impairment
Primary: Area Under the Curve to Infinity (AUCinf) of Apraglutide — 4481; 3744 h*ng/mL
Neoplasms
Primary: Maximum Tolerated Dose (MTD) Based on Number of Dose-limiting Toxicities (DLTs) — NA; NA μg (microgram)
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Bioavailability
Primary: Uncorrected Sapropterin AUC0-t — 989.77; 837.20; 835.52; 791.64 hr*ng/mL
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Herpes Simplex
Primary: Number of Participants Reporting Any Solicited Administration Site Events — 8; 2; 0; 19 Participants
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL
Bioavailability
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (Clast) (AUClast) of Nirmatrelvir — 35020; 31700; 35990…
Morbid Obesity · Bariatric Surgery Candidate
Primary: Mean 24 Hour Visual Analogue Scale (VAS) Pain Score — 1; 3 score on a scale
Prolymphocytic Leukemia · Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose for Selinexor — 40 mg
Alzheimer's Disease
Primary: Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region — 0.429 Correlation coefficient — p=<0.001